<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested doses of low molecular weight heparins in adult patients with a high body mass index (BMI)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested doses of low molecular weight heparins in adult patients with a high body mass index (BMI)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested doses of low molecular weight heparins in adult patients with a high body mass index (BMI)</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">VTE treatment</td> <td class="subtitle1">VTE prophylaxis</td> <td class="subtitle1">Product labeling on use in patients with a high BMI</td> </tr> <tr> <td><strong>Enoxaparin</strong>*</td> <td> <p>Use standard treatment dosing (ie, 1 mg/kg every 12 hours based on <span class="nowrap_whitespace">TBW).<sup>¶</sup></span></p> Once-daily dosing regimens of enoxaparin are <strong>not</strong> <span class="nowrap_whitespace">recommended.<sup>[1]</sup></span></td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> Use standard prophylaxis dosing (ie, 30 mg every 12 hours or 40 mg once <span class="nowrap_whitespace">daily).<sup>[2]</sup></span> Some experts use weight-based dosing (ie, 0.5 mg/kg based on TBW once or twice daily, depending upon level of VTE <span class="nowrap_whitespace">risk).<sup>Δ</sup><sup>[3,4]</sup></span></p> <p><strong>BMI ≥40 kg/m<sup>2</sup>:</strong> Empirically increase standard prophylaxis dose by 30% (ie, from 30 mg every 12 hours to 40 mg every 12 <span class="nowrap_whitespace">hours).<sup>◊</sup><sup>[2]</sup></span> Some experts use weight-based dosing (ie, 0.5 mg/kg based on TBW once or twice daily, depending upon level of VTE <span class="nowrap_whitespace">risk).<sup>Δ</sup><sup>[3-7]</sup></span></p> <p><strong>High VTE-risk bariatric surgery with BMI ≤50 kg/m<sup>2</sup>:</strong> 40 mg every 12 <span class="nowrap_whitespace">hours.<sup>§</sup><sup>[8,9]</sup></span></p> <strong>High VTE-risk bariatric surgery with BMI &gt;50 kg/m<sup>2</sup>:</strong> 60 mg every 12 <span class="nowrap_whitespace">hours.<sup>§</sup><sup>[9]</sup></span></td> <td> <p>Safety and efficacy of prophylactic doses in patients with obesity (BMI <span class="nowrap_whitespace">&gt;30 kg/m<sup>2</sup>)</span> has not been fully determined, and there is no consensus for dose adjustment. Observe carefully for signs and symptoms of <span class="nowrap_whitespace">VTE.<sup>[10]</sup></span></p> Marginal increase observed in mean anti-factor Xa activity using TBW and 1.5 mg/kg once-daily dosing in healthy persons with obesity (BMI 30 to <span class="nowrap_whitespace">48 kg/m<sup>2</sup>)</span> compared with healthy persons with lower <span class="nowrap_whitespace">BMI.<sup>[10]</sup></span></td> </tr> <tr> <td><strong>Dalteparin</strong></td> <td> <p>Use standard treatment dosing (ie, 200 units/kg once daily based on TBW for the first month, followed by 150 units/kg TBW once daily for subsequent <span class="nowrap_whitespace">months).<sup>¶</sup><sup>¥</sup></span></p> <p>May consider using 100 units/kg based on TBW every 12 hours for patients weighing <span class="nowrap_whitespace">≥90 kg.<sup>[11]</sup></span></p> The labeled indication in the United States for adult patients is extended treatment of cancer-associated <span class="nowrap_whitespace">VTE.<sup>[12]</sup></span></td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> Use standard prophylaxis dosing (ie, 5000 units once <span class="nowrap_whitespace">daily).<sup>[2]</sup></span></p> <strong>BMI ≥40 kg/m<sup>2</sup>:</strong> Empirically increase standard prophylaxis dose by 30% (ie, from 5000 units once daily to 6500 units once <span class="nowrap_whitespace">daily).<sup>Δ</sup><sup>◊</sup><sup>[2]</sup></span></td> <td>Cancer-associated VTE treatment: Use TBW-based dosing for patients weighing up to 99 kg. Use a maximum dose of 18,000 units per day for patients weighing <span class="nowrap_whitespace">≥99 kg.<sup>¶</sup><sup>¥</sup><sup>[12]</sup></span></td> </tr> <tr> <td><strong>Nadroparin</strong><br/> (not available in the United States)</td> <td>Use standard treatment dosing (ie, 171 anti-factor Xa units/kg once daily based on TBW or 86 units/kg every 12 hours based on <span class="nowrap_whitespace">TBW).<sup>¶</sup><sup>‡</sup></span></td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> For orthopedic surgery, use weight-based dosing (ie, 38 anti-factor Xa units/kg once daily based on TBW increasing on postoperative day 4 to 57 anti-factor Xa units/kg once daily); for general surgery use standard fixed dosing (ie, 2850 anti-factor Xa units once daily); for medically ill patients use standard fixed dosing (ie, 5700 anti-factor Xa units once daily provided TBW <span class="nowrap_whitespace">&gt;70 kg).<sup>[2]</sup></span></p> <strong>BMI ≥40 kg/m<sup>2</sup>:</strong> For orthopedic surgery, use weight-based dosing (ie, 38 anti-factor Xa units/kg once daily based on TBW increasing on postoperative day 4 to 57 anti-factor Xa units/kg once daily); for general surgery, empirically increase fixed dose by ~30% (ie, increase from 2850 to 3800 anti-factor Xa units once daily); for medically ill patients, empirically increase fixed dose by ~30% (ie, increase from 5700 to 7400 anti-factor Xa units once daily provided TBW <span class="nowrap_whitespace">&gt;70 kg).<sup>Δ</sup><sup>◊</sup><sup>[2]</sup></span></td> <td> <p>Safety and efficacy of LMWHs in high-weight (ie, &gt;120 kg) patients has not been fully determined. Individualized clinical and laboratory monitoring is recommended (Canada product <span class="nowrap_whitespace">monograph).<sup>[13]</sup></span></p> VTE treatment: Use TBW-based dosing for patients weighing up to 100 kg. Use a maximum dose of 17,100 anti-Xa units per day for patients weighing <span class="nowrap_whitespace">&gt;100 kg.<sup>¶</sup><sup>‡</sup><sup>[13]</sup></span></td> </tr> <tr> <td><strong>Tinzaparin</strong><br/> (not available in the United States)</td> <td>Use standard treatment dosing (ie, 175 anti-factor Xa units/kg once daily based on <span class="nowrap_whitespace">TBW).<sup>¶</sup></span></td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> For orthopedic surgery, use weight-based prophylaxis dosing (ie, 50 or 75 anti-factor Xa units/kg based on TBW once daily); for general surgery and medically ill patients, use standard fixed dosing (ie, 3500 <strong>or</strong> 4500 anti-factor Xa units once daily depending upon level of VTE <span class="nowrap_whitespace">risk).<sup>[2]</sup></span></p> <p><strong>BMI ≥40 kg/m<sup>2</sup>:</strong> For orthopedic surgery, use weight-based prophylaxis dosing (ie, 50 or 75 anti-factor Xa units/kg based on TBW once daily); for general surgery and medically ill patients, empirically increase fixed dose by 30% (ie, increase from 3500 to 4500 anti-factor Xa units once daily <strong>or</strong> from 4500 to 6000 anti-factor Xa units once daily depending on level of VTE <span class="nowrap_whitespace">risk).<sup>Δ</sup><sup>◊</sup><sup>[2]</sup></span></p> <strong>Moderate to high VTE-risk bariatric surgery, extended postoperative prophylaxis regimen:</strong> According to a protocol evaluated at one center: Beginning on postoperative day 1: 75 units/kg based on TBW once daily for 10 days; patients weighing &lt;110 kg received 4500 units once daily; patients weighing ≥160 kg received 14,000 units once <span class="nowrap_whitespace">daily.<sup>Δ</sup><sup>§</sup><sup>[14]</sup></span></td> <td>Safety and efficacy in patients weighing &gt;120 kg has not been fully determined. Individualized clinical and laboratory monitoring is recommended (Canada product <span class="nowrap_whitespace">monograph).<sup>[15]</sup></span></td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>All doses shown are for patients with normal kidney function and are for subcutaneous administration. For dose adjustment due to kidney impairment, refer to Lexicomp monographs.</p>
Generally, anti-factor Xa monitoring is not recommended, but it can be considered for patients with BMI <span class="nowrap_whitespace">≥40 kg/m<sup>2</sup></span> who are unstable, experience unexpected thromboembolic or bleeding complications, or require prolonged VTE treatment.</div><div class="graphic_footnotes"><p>VTE: venous thromboembolism; TBW: total body weight, also known as actual body weight; LMWH: low molecular weight heparin; FDA: Food and Drug Administration.</p>
<p>* Conversion: 1 mg enoxaparin is approximately equal to 100 international units enoxaparin.</p>
<p>¶ The 2018 American Society of Hematology (ASH) guidelines and other expert reviews suggest against dose reduction or use of a maximum dose for VTE treatment in patients with a high BMI citing consequences of therapeutic failure and lack of correlation between anti-factor Xa concentrations and increased bleeding <span class="nowrap_whitespace">risk.<sup>[2,16]</sup></span></p>
<p>Δ Rounding of the dose may be necessary depending on product detail. Refer to Lexicomp monograph included with UpToDate.</p>
<p>◊ An empiric dose increase of approximately 30% for fixed prophylactic doses of LMWH for VTE prophylaxis for patients with a high BMI is based on clinical experience, expert opinion, and analysis of pharmacodynamic and clinical outcomes <span class="nowrap_whitespace">data.<sup>[2]</sup></span></p>
<p>§ An optimal approach to thromboprophylaxis in bariatric surgery patients has not been established; there is considerable variability in approach among surgeons and programs. For additional information refer to UpToDate topics on bariatric surgery and institutional protocols.</p>
<p>¥ According to the US FDA approved dalteparin prescribing information, a fixed dose of 18,000 units per day is recommended for patients weighing ≥99 kg who are being treated for cancer-associated <span class="nowrap_whitespace">VTE.<sup>[12]</sup></span> However, guidelines suggest that dalteparin dose should be based on <span class="nowrap_whitespace">TBW.<sup>[2,15]</sup></span> Capped dalteparin dose of 18,000 units per day is <strong>not</strong> recommended.</p>
‡ According to the Canadian approved nadroparin product monograph, a fixed dose of 17,100 units per day is recommended for patients weighing more than <span class="nowrap_whitespace">100 kg.<sup>[13]</sup></span> However, guidelines suggest that nadroparin dose should be based on <span class="nowrap_whitespace">TBW.<sup>[2,16]</sup></span> Capped nadroparin dose of 17,100 units per day is <strong>not</strong> recommended.</div><div class="graphic_reference">References:
<ol>
<li>Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134:191.</li>
<li>Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064.</li>
<li>Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res 2010; 125:220.</li>
<li>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</li>
<li>Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012; 87:740.</li>
<li>Parikh S, Jakeman B, Walsh E, et al. Adjusted-dose enoxaparin for VTE prevention in the morbidly obese. J Pharm Technol 2015; 31:282.</li>
<li>Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg 2013; 206:847.</li>
<li>Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12:19.</li>
<li>Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: Extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4:625.</li>
<li>Enoxaparin sodium. United States prescribing information. Revised April 2020. Available at: <a href="https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=de6fb917-a94a-41ea-9d7d-937d4080ffcd&amp;type=pdf" target="_blank">https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=de6fb917-a94a-41ea-9d7d-937d4080ffcd&amp;type=pdf</a> (Accessed on November 22, 2021).</li>
<li>Al-Yaseen E, Wells PS, Anderson J, et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3:100.</li>
<li>Dalteparin sodium injection. United States prescribing information. Revised September 2021. Available at: <a href="https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;type=pdf" target="_blank">https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&amp;type=pdf</a> (Accessed on November 22, 2021).</li>
<li>Nadroparin calcium injection. Canada product monograph. Revised September 2019. Available at: <a href="https://pdf.hres.ca/dpd_pm/00053484.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00053484.PDF</a> (Accessed on January 14, 2022).</li>
<li>Tseng EK, Kolesar E, Handa P, et al. Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. J Thromb Haemost 2018; 16:2008.</li>
<li>Tinzaparin sodium injection. Canada product monograph. Revised May 2017. Available at: <a href="https://pdf.hres.ca/dpd_pm/00040736.PDF" target="_blank">https://pdf.hres.ca/dpd_pm/00040736.PDF</a> (Accessed on November 22, 2021).</li>
<li>Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Optimal management of anticoagulation therapy. Blood Adv 2018; 27:3257.</li>
</ol></div><div id="graphicVersion">Graphic 65464 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
